Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: Dual inhibitors of EGFR and Src protein tyrosine kinases

• Published in: European journal of medicinal chemistry Vol. 55; pp. 39 - 48
• Main Authors: Lin, Jinsheng, Shen, Wei, Xue, Jingwei, Sun, Juan, Zhang, Xue, Zhang, Can
• Format: Journal Article
• Language: English
• Published: ISSY-LES-MOULINEAUX Elsevier Masson SAS 01.09.2012; Elsevier
• Subjects: Anti-tumor agents; Biological and medical sciences; Cell Line, Tumor; Cell Proliferation - drug effects; Chemistry, Medicinal; EGFR inhibitor; Humans; Life Sciences & Biomedicine; Medical sciences; Miscellaneous; Molecular Docking Simulation; Oxazolo[4,5-g]quinazolin-2(1H)-one scaffold; Pharmacology & Pharmacy; Pharmacology. Drug treatments; Protein Conformation; Protein Kinase Inhibitors - chemical synthesis; Protein Kinase Inhibitors - chemistry; Protein Kinase Inhibitors - metabolism; Protein Kinase Inhibitors - pharmacology; Protein tyrosine kinases (PTK); Quinazolines - chemical synthesis; Quinazolines - chemistry; Quinazolines - metabolism; Quinazolines - pharmacology; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Receptor, Epidermal Growth Factor - chemistry; Receptor, Epidermal Growth Factor - metabolism; Science & Technology; Src inhibitor; src-Family Kinases - antagonists & inhibitors; src-Family Kinases - chemistry; src-Family Kinases - metabolism; Protein tyrosine kinases (PTK); Src inhibitor; Anti-tumor agents; Oxazolo[4,5-g]quinazolin-2(1H)-one scaffold; EGFR inhibitor; NNLYOFSWWFKIMS-UHFFFAOYSA-N; IRREVERSIBLE INHIBITORS; CANCER; GROWTH-FACTOR RECEPTOR; NEUTRAL 5-SUBSTITUTED 4-ANILINOQUINAZOLINES; POTENT; ORALLY-ACTIVE INHIBITORS; EXPRESSION; BINDING; Oxazolo[4,5-g]quinazolin-2(1H)-one; scaffold
• DOI: 10.1016/j.ejmech.2012.06.055
• ISSN: 0223-5234

Quinazoline-containing derivatives are an important class of synthetic products and represent an attractive scaffold for EGFR inhibitors. A series of oxazolo[4,5-g]quinazolin-2(1H)-one derivatives were synthesized and the EGFR and Src inhibition activities were evaluated using Gefitinib as lead compound. The three most potent compounds 5y, 5l and 5a each inhibited EGFR at the IC50 value of 61 nM, 67 nM and 78 nM. Among them, 5c also demonstrated excellent inhibition activity against Src with the IC50 value of 3.1 μM. Several of these derivatives also showed good anti-proliferation effects against KB and A498 cells. Compounds 5y showed more potent inhibition activity against EGFR and anti-proliferation activity against KB and A498 cell lines than Gefitinib. [Display omitted] ► New oxazolo[4,5-g]quinazolin-2(1H)-one structure derivatives were synthesized. ► Two compounds showed more potent inhibition activities against EGFR than Gefitinib. ► 5y was more effective in the inhibition of KB and A498 cell lines than Gefitinib.